지원사업
학술연구/단체지원/교육 등 연구자 활동을 지속하도록 DBpia가 지원하고 있어요.
커뮤니티
연구자들이 자신의 연구와 전문성을 널리 알리고, 새로운 협력의 기회를 만들 수 있는 네트워킹 공간이에요.
초록· 키워드
오류제보하기
Sodium-glucose cotransporter 2 inhibitors are antidiabetic drugs that increase urinary glucose excretion by inhibiting proximal tubular reabsorption of glucose in the kidney. Some sodium-glucose cotransporter 2 inhibitors have been shown to afford effective glycemic control and to decrease the risks of major adverse cardiovascular events. However, these drugs may increase the risk of diabetic ketoacidosis. This is a rare complication that occurs in less than 0.1% of treated patients with type 2 diabetes.
The condition may be euglycemic, and is triggered by controllable precipitating factors such as surgery, infection, and insulin reduction or omission. It is important to understand individual patient profiles and to prevent diabetic ketoacidosis by appropriate prescribing, by withholding sodium-glucose cotransporter 2 inhibitors when indicated, and by counseling patients on sick day management.
목차
등록된 정보가 없습니다.
참고문헌 (22)
참고문헌 신청
Barski L / 2013 / Comparison of diabetic ketoacidosis in patients with type-1 and type-2diabetes mellitus / Am J Med Sci 345 : 326 ~ 330
Bolinder J / 2012 / Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequa
Chilton R / 2015 / 4B.02: The sodium glucose cotransporter 2 inhibitor empagliflozin reduces blood pressure and markers of arterial stiffness and vascular resistance in type
Davies MJ / 2015 / Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus / Diabetes Obes Metab 17 : 426 ~ 429
DeFronzo RA / 2012 / The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia / Diabetes Obes Metab 14 : 5 ~ 14
Bolinder J / 2012 / Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequa
Chilton R / 2015 / 4B.02: The sodium glucose cotransporter 2 inhibitor empagliflozin reduces blood pressure and markers of arterial stiffness and vascular resistance in type
Davies MJ / 2015 / Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus / Diabetes Obes Metab 17 : 426 ~ 429
DeFronzo RA / 2012 / The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia / Diabetes Obes Metab 14 : 5 ~ 14
함께 읽어보면 좋을 논문
논문 유사도에 따라 DBpia 가 추천하는 논문입니다. 함께 보면 좋을 연관 논문을 확인해보세요!
-
Off-target Effects of Sodium-glucose Cotransporter 2 (SGLT-2) Inhibitor in Cardiovascular Disease
Korean Circulation Journal
2020 .01
-
제2형 당뇨병 환자에서 장기간의 Sodium-glucose Cotransporter 2 억제제 치료가 신장기능에 미치는 효과
대한내과학회지
2020 .08
-
Sodium-Glucose Cotransporter 2 Inhibitor Improves Neurological Outcomes in Diabetic Patients With Acute Ischemic Stroke
대한뇌졸중학회지
2024 .05
-
Benefit and Safety of Sodium-Glucose Co-Transporter 2 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2024 .09
-
Sodium Glucose Cotransporter-2 Inhibitors as an Add-on Therapy to Metformin Plus Dipeptidyl Peptidase-4 Inhibitor in Patients with Type 2 Diabetes
Yonsei Medical Journal
2022 .06
-
SGLT2 억제제와 만성 콩팥병
대한내과학회지
2024 .04
-
Sodium/glucose Co-Transporter 2 Inhibitor, Empagliflozin, Alleviated Transient Expression of SGLT2 after Myocardial Infarction
Korean Circulation Journal
2021 .01
-
Predictors of the Therapeutic Efficacy and Consideration of the Best Combination Therapy of Sodium-Glucose Co-transporter 2 Inhibitors
Diabetes and Metabolism Journal
2019 .01
-
Use of dapagliflozin in patients with advanced diabetic kidney disease
Kidney Research and Clinical Practice
2018 .01
-
Cardiovascular Outcome Trials of Sodium Glucose Cotransporter 2 Inhibitor and Its Possible Cardioprotective Mechanism
지질·동맥경화학회지
2018 .01
-
Antidiabetic effect of Luffa cylindrical extract against the streptozotocin induced diabetes via alteration of glucose transporter 2 and sodium-glucose cotransporter 1
Annals of Hepato-Biliary-Pancreatic Surgery
2021 .12
-
Sodium-glucose cotransporter-2 inhibitor for renal function preservation in patients with type 2 diabetes mellitus: a Korean Diabetes Association and Korean Society of Nephrology consensus statement
Kidney Research and Clinical Practice
2020 .01
-
Clinical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitor and Glucagon-Like Peptide-1 Receptor Agonist Combination Therapy in Type 2 Diabetes Mellitus: Real-World Study
Diabetes and Metabolism Journal
2022 .07
-
Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Weight Reduction in Overweight and Obese Populations without Diabetes: A Systematic Review and a Meta-Analysis
Journal of Obesity & Metabolic Syndrome
2021 .12
-
Anti-Inflammatory Effect for Atherosclerosis Progression by Sodium-Glucose Cotransporter 2 (SGLT-2) Inhibitor in a Normoglycemic Rabbit Model
Korean Circulation Journal
2020 .01
-
Cardiovascular Safety of Sodium Glucose Cotransporter 2 Inhibitors as Add-on to Metformin Monotherapy in Patients with Type 2 Diabetes Mellitus
Diabetes and Metabolism Journal
2021 .01
-
New Era for Renal-Protective Therapy in Type 2 Diabetes: Better Renal Outcomes in Patients with Type 2 Diabetes Taking Sodium-Glucose Cotransporter 2 Inhibitors versus Dipeptidyl Peptidase-4 Inhibitors
Endocrinology and Metabolism
2021 .01
-
Use of SGLT-2 Inhibitors in Patients with Type 2 Diabetes Mellitus and Abdominal Obesity: An Asian Perspective and Expert Recommendations
Diabetes and Metabolism Journal
2020 .01
-
새로운 심부전 약제, SGLT2 억제제
대한내과학회지
2023 .04
-
Comparative Renal Effects of Dipeptidyl Peptidase-4 Inhibitors and Sodium-Glucose Cotransporter 2 Inhibitors on Individual Outcomes in Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
Endocrinology and Metabolism
2021 .01
이 논문의 저자 정보
최근 본 자료
댓글(0)
0